ERBB2 and breast neoplasm: Next, MTT assays were performed to evaluate the ability of ADP106–109 to inhibit cell growth on BT474 (HER2+), and MDA-MB-231, (“triple-negative” or TNBC) human breast tumor cell lines (Fig. S9 and S10).